| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lindsey Marwood, Megan Croal, Sunil Mistry, Hollie Simmons, Joyce Tsai, Matthew B Young, Guy M Goodwi. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. Journal of psychiatric research. vol 180. 2024-10-20. PMID:39427449. |
data from 233 participants with treatment-resistant depression (trd) who received 25 mg, 10 mg, or 1 mg of investigational drug comp360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, compass pathfinder ltd.), administered with psychological support, were compared for groups of participants who either discontinued one or more antidepressant drugs during screening or entered the trial antidepressant drug free. |
2024-10-20 |
2024-10-23 |
human |
| Izabela Szpręgiel, Agnieszka Bysie. Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases. Pharmacological reports : PR. 2024-10-16. PMID:39412581. |
therefore, the aim of this mini-review is to discuss the available literature data indicating the impact of psilocybin on glutamatergic neurotransmission and its therapeutic effects in the treatment of depression and other diseases of the nervous system. |
2024-10-16 |
2024-10-18 |
Not clear |
| Gottfried R S Treviranu. Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin? Psychiatria Danubina. vol 36. issue Suppl 2. 2024-10-08. PMID:39378462. |
depression astonishingly can be stopped instantly by electrotherapies or through some psychedelics like psilocybin. |
2024-10-08 |
2024-10-11 |
caenorhabditis_elegans |
| Jack D C Dahan, David Dadiomov, Tijmen Bostoen, Albert Daha. Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. Npj mental health research. vol 3. issue 1. 2024-10-05. PMID:39369173. |
there is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (sud). |
2024-10-05 |
2024-10-08 |
Not clear |
| Lucas Henrique Junges, Marcelo Müller-Santo. Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications. Biotechnology progress. 2024-10-04. PMID:39366919. |
psilocybin, a notable tryptamine, has garnered attention for its therapeutic potential in treating mental health disorders like depression and anxiety. |
2024-10-04 |
2024-10-07 |
Not clear |
| Sara Ellis, Catherine Bostian, Wendy Feng, Eileen Fischer, Garrett Schwartz, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael Ostacher, Scott Aaronson, Trisha Suppe. Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study. Journal of affective disorders. 2024-09-29. PMID:39343309. |
single-dose psilocybin for u.s. military veterans with severe treatment-resistant depression - a first-in-kind open-label pilot study. |
2024-09-29 |
2024-10-02 |
Not clear |
| Sara Ellis, Catherine Bostian, Wendy Feng, Eileen Fischer, Garrett Schwartz, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael Ostacher, Scott Aaronson, Trisha Suppe. Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study. Journal of affective disorders. 2024-09-29. PMID:39343309. |
this is the first study to evaluate the efficacy and safety of psilocybin in veterans with severe treatment-resistant depression (trd). |
2024-09-29 |
2024-10-02 |
Not clear |
| Stacey B Armstrong, Alan K Davi. Psychedelic research at a crossroads. Science (New York, N.Y.). vol 385. issue 6715. 2024-09-19. PMID:39298596. |
although results of trials using mdma for trauma or psilocybin for depression are promising, pat is controversial because many questions about its safety and effectiveness are unanswered. |
2024-09-19 |
2024-09-22 |
Not clear |
| Zifan Zhen, Xueqiang Sun, Shiying Yuan, Jiancheng Zhan. Psychoactive substances for the treatment of neuropsychiatric disorders. Asian journal of psychiatry. vol 101. 2024-09-07. PMID:39243659. |
hallucinogens like lysergic acid diethylamide and psilocybin primarily target the 5-ht2a receptor agonist-2 (5-ht2ar), inducing substantial perceptual and cognitive shifts that facilitate deep psychological introspection and significant therapeutic advances, particularly in patients suffering from depression and anxiety disorders. |
2024-09-07 |
2024-09-10 |
Not clear |
| Gianmarco Salvetti, Daniele Saccenti, Andrea Stefano Moro, Jacopo Lamanna, Mattia Ferr. Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. Brain sciences. vol 14. issue 8. 2024-08-29. PMID:39199520. |
comparison between single-dose and two-dose psilocybin administration in the treatment of major depression: a systematic review and meta-analysis of current clinical trials. |
2024-08-29 |
2024-09-01 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a promising potential in the treatment of depressive disorders. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
a review of psilocybin use in patients with depressive disorders is presented.a search was conducted investigating the use of psilocybin in patients with depressive disorders and treatment resistant depression via pubmed/medline, embase, and google scholar in october 2023; all publication types were permitted and limited for english-language. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
keyword search terms included: "psilocybin" or "psychedelics" and "depression", or "major depressive disorder", or "treatment-resistant depression". |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
controlled and uncontrolled clinical trials utilizing psilocybin with psychological support for major depressive disorder and treatment-resistant depression, as well as in patients with depression and cancer related anxiety have demonstrated immediate and sustained antidepressant and anxiolytic effects. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
psilocybin may offer a valuable contribution as an option to the currently available pharmacological and psychotherapeutic agents for patients with major depressive disorders, treatment-resistant depression as well as for patients with depression and comorbid terminal cancer. |
2024-08-23 |
2024-08-25 |
Not clear |
| Baeleigh VanderZwaag, Albert Garcia-Romeu, Mauricio A Garcia-Barrer. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. Therapeutic advances in psychopharmacology. vol 14. 2024-08-12. PMID:39132012. |
psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. |
2024-08-12 |
2024-08-14 |
Not clear |
| André Do, Vanessa Michaud, Jean-François Stephan, Miltiadis Moreau, Élise Benoît, Félix-Antoine Bérubé, Antoine Bibaud-De Serres, Alain Taillefer, Philippe Vincen. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Frontiers in psychiatry. vol 15. 2024-08-01. PMID:39086732. |
psilocybin has reemerged as a promising treatment for difficult-to-treat depression (dtd). |
2024-08-01 |
2024-08-03 |
Not clear |
| Amanda Paige Hanstein, Chance Felchli. Treating Anxiety and Depression With Psilocybin Therapy. Radiologic technology. vol 95. issue 6. 2024-07-30. PMID:39079732. |
treating anxiety and depression with psilocybin therapy. |
2024-07-30 |
2024-08-02 |
Not clear |
| Husam Bader, Husam Farraj, Joud Maghnam, Yazan Abu Oma. Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis. World journal of clinical oncology. vol 15. issue 7. 2024-07-29. PMID:39071471. |
psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, is known for its effects on anxiety and depression. |
2024-07-29 |
2024-08-02 |
Not clear |
| Siyi Zheng, Rong Ma, Yang Yang, Gang L. Psilocybin for the treatment of Alzheimer's disease. Frontiers in neuroscience. vol 18. 2024-07-26. PMID:39050672. |
psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. |
2024-07-26 |
2024-07-28 |
Not clear |